Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy obesity drug, as it battled pressure from compounding pharmacies in the United States and rival Eli Lilly.

Novo Nordisk said second-quarter sales of its blockbuster Wegovy weight-loss drug soared 67% on year, despite waves of U.S. patients using generic unbranded versions of the drug.The Danish company last week slashed full-year guidance,

Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, particularly in the U.S. The company is taking legal action against compounding pharmacies and exploring direct-to-consumer sales to remain competitive amid declining stock and sales expectations.